Related Experiment Video
Updated: Jun 3, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
A network-based multi-target computational estimation scheme for anticoagulant activities of compounds
Qian Li1, Xudong Li, Canghai Li
1Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, People's Republic of China.
Plos One
|March 30, 2011
Summary
This study introduces a novel computational method combining network efficiency and molecular docking to predict anticoagulant activity. The approach effectively identifies key targets in the clotting cascade, aiding drug discovery for complex diseases.
Area of Science:
- Computational systems biology
- Pharmacology
- Network biology
Background:
- Traditional virtual screening often overlooks complex disease systems, limiting drug discovery for multifaceted conditions.
- Advancements in network and systems biology enable virtual screening for complex diseases using network estimation.
- There is a need for computational methods to assess compound efficacy in complex disease systems, considering target importance and partial inhibition.
Purpose of the Study:
- To develop and validate a novel computational approach for estimating anticoagulant activities of compounds.
- To integrate multi-target docking affinity predictions with biological network efficiency analysis.
- To identify critical targets and pathways within the human clotting cascade for anticoagulant drug development.
Main Methods:
- Developed a novel approach integrating multi-target docking affinity predictions with biological network efficiency analysis.
- Analyzed the human clotting cascade to identify the most fragile enzymes (Factor Xa, Thrombin) and biological processes.
- Applied the combined network efficiency and molecular docking method to estimate anticoagulant activities of argatroban intermediates and natural products.
Main Results:
- Factor Xa and Thrombin identified as the most fragile enzymes in the human clotting cascade.
- The catalytic reaction mediated by complex IXa:VIIIa and the formation of complex VIIIa:IXa recognized as the most fragile biological processes.
- A strong correlation (r=0.671) was observed between experimental data and decreased network efficiency, validating the approach.
Conclusions:
- Proposed a network-based, multi-target computational estimation method for compound anticoagulant activities.
- The method combines network efficiency analysis with molecular docking scoring functions.
- This approach serves as a promising computational systems biology tool for identifying anticoagulant activities in drug discovery.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:24One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation
This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
On...
01:20Estimation of k and VD of Aminoglycosides
Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:23Drug Concentrations: Measurements
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma —...
Plasma —...
01:15Pharmacodynamic Models: Linear Concentration–Effect Model
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...